PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
By PVI, PeerView Institute for Medical Education
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 28
Reviews: 0
Episodes: 392
Description
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
| Episode | Date |
|---|---|
|
Fuad El Rassi, MD, Modupe Idowu, MD - A New Script for SCD Care: Guidance on Patient-Centric Treatment Decisions With Innovative Therapeutics
|
Nov 21, 2024 |
|
Jennifer Chan, MD, MPH - Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes
|
Nov 21, 2024 |
|
Andrea Cercek, MD - Accelerating Personalized Care in CRC: The Prominent Role of Predictive Biomarkers and Immunotherapy Platforms in Early and Advanced Disease
|
Nov 12, 2024 |
|
Andrew J. Wagner, MD, PhD - Building the Alliance in Dedifferentiated Liposarcoma: Integrating Personalized, Multidisciplinary Care With Innovative MDM2 Antagonists in Advanced Disease
|
Nov 11, 2024 |
|
Kassandra August-Marcucio, DNP, APRN, ACNP-BC, SANE, Grace Cullen, DNP, FNP-BC, AOCNP, PMGT-BC, FPCN - Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery
|
Nov 11, 2024 |
|
Meghan C. Thompson, MD - Building Resilient Care Communities for R/R CLL: Collaborative Sequential Approaches in an Era of Innovative Options
|
Nov 11, 2024 |
|
Ibiayi Dagogo-Jack, MD / Jay M. Lee, MD - Reinforcing Precision Tactics in Genomically Altered Resectable NSCLC: Collaborative Workflows and Personalized Solutions for Integration of Adjuvant EGFR- and ALK-Targeted Therapies
|
Oct 28, 2024 |
|
Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Integrating Immunotherapy in Resectable NSCLC: How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways
|
Oct 28, 2024 |
|
Guillermo Garcia-Manero, MD - Resetting Standards in MDS: New Principles for Integrating Innovative Therapy Into Risk-Adapted Care
|
Oct 22, 2024 |
|
Arndt Vogel, MD, PhD - Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease
|
Oct 22, 2024 |
|
Professor Stephen Johnston, MA, PhD - How to Make Multifactorial Clinical Decisions in HR+, HER2- EBC and MBC: Guiding Precision Amid Growing Complexity
|
Oct 22, 2024 |
|
William G. Wierda, MD, PhD - Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care
|
Oct 04, 2024 |
|
Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC
|
Oct 04, 2024 |
|
Taofeek K. Owonikoko, MD, PhD - Taking a BiTE Out of SCLC: Are You Ready for a New Wave of DLL3-Targeting T-Cell Engagers and Other Therapies?
|
Oct 04, 2024 |
|
Prof. Solange Peters, MD, PhD - Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care
|
Oct 02, 2024 |
|
Naval Daver, MD, Tapan Kadia, MD - Opportunity Knocks in AML: Guidance on Achieving Truly Personalized Care in Challenging Populations with Modern Therapeutics
|
Oct 02, 2024 |
|
Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer
|
Oct 02, 2024 |
|
Roy S. Herbst, MD, PhD - Elevating Care in Resectable Stage I-III NSCLC: Targeted Therapy and Immunotherapy at the Forefront of Multimodal Treatment Strategies
|
Oct 02, 2024 |
|
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management
|
Oct 02, 2024 |
|
Shannon N. Westin, MD, MPH, Ramez N. Eskander, MD - Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients
|
Oct 02, 2024 |
|
Stephen V. Liu, MD - Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects
|
Oct 02, 2024 |
|
Stephanie L. Graff, MD, FACP, FASCO - Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast Cancer: Practical Training on Individualizing CDK4/6 Inhibitor Treatment to Enhance Adherence, Quality of Life, and Outcomes
|
Sep 23, 2024 |
|
Sara M. Tolaney, MD, MPH - Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC
|
Sep 06, 2024 |
|
Hope S. Rugo, MD, FASCO - Exchanging Ideas on How to Navigate Patient-Centric Clinical Decisions in Integration of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer
|
Sep 06, 2024 |
|
Bradley J. Monk, MD, FACS, FACOG - Advancing Immunotherapy: Revolutionizing Cervical Cancer Treatment
|
Aug 28, 2024 |
|
Christopher L. Moertel, MD - Mapping a New Treatment Journey in NF1: New Developments With MEKi for Pediatric and Adult Patients With NF1-Plexiform Neurofibromas
|
Aug 27, 2024 |
|
Hussein Tawbi, MD, PhD - Renovating Frontline Care for Metastatic Melanoma: Guidance on Upgrading to Combination Immunotherapy Standards Across Disease Presentations
|
Aug 15, 2024 |
|
Angela Lamarca, MD, PhD, MSc - Prioritising Patient-Centric Care in Biliary Tract Cancer: Leveraging Immunotherapy Platforms to Overcome Challenges in the Advanced Setting
|
Aug 15, 2024 |
|
Univ.-Prof. Dr. Peter R. Galle - Mastering Multidirectional Tactics in HCC: Expert Guidance on Emerging Trends With Systemic Therapy Options Across the Disease Continuum
|
Jul 26, 2024 |
|
Ticiana Leal, MD - Achieving Optimal SCLC Care With Established and Innovative Therapies: Latest Evidence, Key Ongoing Trials, and Practical Considerations for Real-World Practice
|
Jul 26, 2024 |
|
Naval Daver, MD - Unleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics
|
Jul 18, 2024 |
|
Hussein Tawbi, MD, PhD / Prof. Christian Blank, MD, PhD - Deploying the Immune GAMBIT Against Melanoma: Guidance on Advances and Medical Breakthroughs With ImmunoTherapy
|
Jul 18, 2024 |
|
Maissaa Janbain, MD, MSCR - Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches
|
Jul 18, 2024 |
|
Paolo Ghia, MD, PhD - Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms
|
Jul 16, 2024 |
|
Pier Luigi Zinzani, MD, PhD - Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy
|
Jul 16, 2024 |
|
Joyce O’Shaughnessy, MD - Rising to the Challenges of Early and Advanced HR+ Breast Cancer: Examining Complex Evidence to Inform Clinical Decisions
|
Jul 16, 2024 |
|
Stephen V. Liu, MD - Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024
|
Jul 16, 2024 |
|
Ruben A. Mesa, MD, FACP - CONTROL Myelofibrosis: Current Options, New Treatment Principles, and Opportunities to Leverage JAKi Platforms and Novel MOAs
|
Jul 03, 2024 |
|
Petros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision
|
Jul 03, 2024 |
|
Komal Jhaveri, MD, FACP - Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions
|
Jul 03, 2024 |
|
Sandip Patel, MD - Illuminating the Path With Immunotherapy for Metastatic, Locally Advanced, and Early-Stage NSCLC: A Guide to Patient Assessment, Treatment Selection, and Multidisciplinary Collaboration Across the Disease Continuum
|
Jul 03, 2024 |
|
Prof. Mohamad Mohty, MD, PhD - Expanding Frontline Frontiers in MM: Insights on Delivering Modern Care With Innovative CD38 Quadruplet Platforms
|
Jul 03, 2024 |
|
Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms
|
Jul 03, 2024 |
|
Sundar Jagannath, MD, FASCO - Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care
|
Jul 03, 2024 |
|
Mansoor Raza Mirza, MD / Ana Oaknin, MD, PhD - Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens
|
Jul 03, 2024 |
|
Barbara Burtness, MD - Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms
|
Jul 03, 2024 |
|
Andrea Necchi, MD - Candid Conversations on Modern Urothelial Cancer Management: Personalizing Patient Care Using the Latest Evidence and Innovative Therapeutic Strategies
|
Jun 28, 2024 |
|
Petros Grivas, MD, PhD - Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care
|
Jun 28, 2024 |
|
Nicole Lamanna, MD - Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations
|
Jun 26, 2024 |
|
Karim Fizazi, MD, PhD - Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer: Experts Put the Pressure on Key Evidence and Real-World Strategies to Optimize Patient Care
|
Jun 24, 2024 |
|
Yelena Y. Janjigian, MD - Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC
|
Jun 24, 2024 |
|
Manish A. Shah, MD, FASCO - Catalysts for Change in Gastric and GEJ Cancer: Digesting New Evidence and Future Directions of Care With Innovative Immunotherapy and Targeted Platforms
|
Jun 24, 2024 |
|
Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting
|
Jun 19, 2024 |
|
Prof. Mohamad Mohty, MD, PhD / Caitlin Costello, MD - Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM
|
Jun 11, 2024 |
|
Riad Salem, MD, MBA / Mark Yarchoan, MD - Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit
|
Jun 11, 2024 |
|
Suzanne Lentzsch, MD, PhD / Joshua Richter, MD - “Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
|
Jun 03, 2024 |
|
Jessica Donington, MD - Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches
|
Jun 03, 2024 |
|
Sarah Hayward, PharmD, BCOP / Ambar Khan, PharmD, BCOP - A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care
|
Jun 03, 2024 |
|
Sia Daneshmand, MD / Matthew D. Galsky, MD - Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Strategies for Integrating the Latest Evidence and Treatment Advances
|
May 27, 2024 |
|
Nicholas J. Short, MD - Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies and MRD-Guided Strategies Across Disease Settings
|
May 27, 2024 |
|
Jamie Carroll, APRN, CNP, MSN - Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education
|
May 24, 2024 |
|
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations
|
May 24, 2024 |
|
Oliver Sartor, MD - On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer
|
May 24, 2024 |
|
Neal D. Shore, MD, FACS - Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum
|
May 24, 2024 |
|
Marianne Davies, DNP, ACNP, AOCNP, FAAN / Beth Sandy, MSN, CRNP, FAPO - Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care
|
May 20, 2024 |
|
Alicia K. Morgans, MD, MPH, Neal D. Shore, MD, FACS - Treatment Advances and Individualized Therapeutic Strategies in Prostate Cancer: Expert Insights on Key Evidence, Practical Tips for Personalized Therapy, and Clinical Integration Approaches
|
May 08, 2024 |
|
Lecia V. Sequist, MD, MPH - Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals
|
May 06, 2024 |
|
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO - Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy With Antibody Platform
|
May 06, 2024 |
|
Prof. Nicolas Girard, MD, PhD / Aaron Lisberg, MD - Charting a New Path to Better Outcomes With TROP2-Targeting ADCs in Lung Cancer: Unveiling Potential, Shaping Tomorrow
|
May 06, 2024 |
|
Laura S. Dominici, MD, FACS - Unraveling the Complex Choices in Early Breast Cancer: A Roadmap to Informed Multidisciplinary Decisions About Assessment and Treatment
|
Apr 25, 2024 |
|
Olalekan Oluwole, MBBS, MPH - Democratizing the CAR-T Experience: The Principles and Practice of Outpatient Cellular Therapy
|
Apr 25, 2024 |
|
Carlos G. Romo, MD, Aimee Sato, MD - Precision and Progress Against NF1: Solutions for Better Outcomes With MEKi and Multimodal Care for NF1 pNF and Other Tumors
|
Apr 25, 2024 |
|
Lipika Goyal, MD, MPhil / Riad Salem, MD, MBA - The Convergence of Interventional Radiologists and Oncologists in HCC: Shared Decision-Making and Care Coordination at the Center of Personalized Care Across the Disease
|
Apr 17, 2024 |
|
Meghan C. Thompson, MD - From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
|
Apr 17, 2024 |
|
Jennifer Wargo, MD, MMSc - New Chapters in the Immunotherapy Story for Melanoma: Collaborative Care and Next Steps With Adjuvant and Neoadjuvant Therapy
|
Apr 17, 2024 |
|
Bradley J. Monk, MD, FACS, FACOG - Advancing ADCs in Gynecologic Cancers: Expert Insights on Recent Evidence, Implementation Strategies, and Patient Care
|
Apr 10, 2024 |
|
Kathleen N. Moore, MD, MS - Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies
|
Apr 10, 2024 |
|
Prof. Dr. med. Stephan Stilgenbauer - Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations
|
Apr 10, 2024 |
|
Sergio A. Giralt, MD, FACP - Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies
|
Mar 28, 2024 |
|
Sandip Patel, MD - The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC
|
Mar 27, 2024 |
|
Prof. Mohamad Mohty, MD, PhD / Christine N. Duncan, MD - Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management
|
Mar 27, 2024 |
|
Roy F. Chemaly, MD, MPH, FIDSA, FACP / Genovefa Papanicolaou, MD, FIDSA, Fellow ASCT - Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents
|
Mar 27, 2024 |
|
Zack DeFilipp, MD - Closing the Treatment Gap in Acute and Chronic GVHD: Improving Post-HCT Outcomes With Innovative Targeted Approaches
|
Mar 27, 2024 |
|
Krina Patel, MD, MSc - Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses and Enduring Efficacy
|
Mar 27, 2024 |
|
Hussein Tawbi, MD, PhD - Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options
|
Mar 26, 2024 |
|
Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic
|
Mar 26, 2024 |
|
Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer
|
Mar 14, 2024 |
|
Joshua Sabari, MD - Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon
|
Mar 14, 2024 |
|
Amy Shapiro, MD - A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations
|
Mar 14, 2024 |
|
Matthew D. Galsky, MD - Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum
|
Mar 14, 2024 |
|
Prof. Laurence Albiges, MD, PhD - Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors and Preparing for Innovative Delivery Approaches in the Clinic
|
Mar 14, 2024 |
|
Alok A. Khorana, MD, FACP, FASCO - REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism
|
Mar 11, 2024 |
|
Benjamin Levy, MD - Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care
|
Mar 11, 2024 |
|
Reshma L. Mahtani, DO - A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights
|
Mar 11, 2024 |
|
Robert Dreicer, MD, MS, MACP, FASCO - Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies
|
Feb 29, 2024 |
|
Kurt A. Schalper, MD, PhD - PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Biomarker Testing and Pathologic Response Assessment
|
Feb 28, 2024 |
|
Sumanta Kumar Pal, MD, FASCO - Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies
|
Feb 28, 2024 |
|
Jessica Donington, MD / Jonathan D. Spicer, MD, PhD, FRCSC - A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC
|
Feb 27, 2024 |
|
Lipika Goyal, MD, MPhil / Riad Salem, MD, MBA - Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum
|
Feb 21, 2024 |
|
Brendon M. Stiles, MD - Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC
|
Feb 21, 2024 |
|
Erika Hamilton, MD - Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
|
Feb 20, 2024 |
|
Milind Javle, MD - Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
|
Feb 20, 2024 |
|
Joyce O’Shaughnessy, MD - Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
|
Feb 12, 2024 |
|
Meghan C. Thompson, MD, Catherine C. Coombs, MD - From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
|
Feb 12, 2024 |
|
Ghassan Abou-Alfa, MD, MBA - Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches
|
Feb 12, 2024 |
|
Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC
|
Feb 09, 2024 |
|
Aditya Bardia, MD, MPH - Revolutionizing Treatment and Equity in HR+/HER2- Early Breast Cancer With CDK4/6 Inhibitors
|
Feb 09, 2024 |
|
Vivian G. Oehler, MD - The Sequel to the Targeted Therapy Era in CML: Guidance on Integrating Novel Options Into Cohesive Sequential Care
|
Feb 08, 2024 |
|
Erika Hamilton, MD - Mastering the Art of Precision in the Treatment of HR+ Early and Metastatic Breast Cancer: Risk Assessment, Prognostic Testing, and Selection and Sequencing of Therapies
|
Jan 31, 2024 |
|
Prof. John G. Gribben, MD, DSc - Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management
|
Jan 31, 2024 |
|
Jaffer A. Ajani, MD, FASCO - Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care
|
Jan 31, 2024 |
|
John L. Marshall, MD - Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
|
Jan 31, 2024 |
|
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey
|
Jan 31, 2024 |
|
Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care
|
Jan 17, 2024 |
|
Sergio A. Giralt, MD, FACP and Selina Luger, MD, FRCPC - Achieving Next-Level Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine
|
Jan 17, 2024 |
|
María Díez Campelo, MD, PhD - Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care With Team-Based Diagnosis and Treatment
|
Jan 17, 2024 |
|
Steven Brem, MD - Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches
|
Jan 12, 2024 |
|
Shmuel Shoham, MD - Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents
|
Jan 12, 2024 |
|
Sara A. Hurvitz, MD, FACP - Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer
|
Jan 12, 2024 |
|
Manmeet S. Ahluwalia, MD, MBA, FASCO - Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy
|
Jan 12, 2024 |
|
Nikhil C. Munshi, MD - Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options
|
Jan 12, 2024 |
|
Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies
|
Jan 12, 2024 |
|
Benjamin Levy, MD - Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer
|
Dec 28, 2023 |
|
Matthew A. Gubens, MD, MS, FASCO - Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care
|
Dec 27, 2023 |
|
Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum
|
Dec 21, 2023 |
|
Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
|
Dec 21, 2023 |
|
Sumanta Kumar Pal, MD, FASCO - Leveling Up Our RCC Care Strategy: Real-World Translation of Key Evidence Across Treatment Settings
|
Dec 14, 2023 |
|
Bradley J. Monk, MD, FACS, FACOG - The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer
|
Dec 13, 2023 |
|
Thomas G. Martin, III, MD - The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms
|
Dec 12, 2023 |
|
Beth Sandy, MSN, CRNP, FAPO - Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
|
Dec 06, 2023 |
|
Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
|
Dec 06, 2023 |
|
Mrinal Gounder, MD - Getting to Know the New Desmoid Tumor ICD-10-CM Codes and Why They Matter: Practical Guidance for Integrating the New Codes and Navigating the Implications
|
Dec 01, 2023 |
|
Luke Maese, DO - Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
|
Nov 24, 2023 |
|
Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
|
Nov 24, 2023 |
|
Paolo Tarantino, MD - Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care
|
Nov 24, 2023 |
|
Ticiana Leal, MD - Optimizing the Care of Patients With SCLC in the Community Setting: How to Make the Most of the Latest Therapeutic Advances and Team-Based Best Practices
|
Nov 07, 2023 |
|
John C. Byrd, MD - Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy
|
Nov 07, 2023 |
|
Jessica Donington, MD - Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: Leveraging Science, Enhancing Collaboration, and Improving Outcomes With Neoadjuvant and/or Adjuvant Checkpoint Inhibition
|
Oct 31, 2023 |
|
Erik P. Sulman, MD, PhD - Tumor Treating Fields as an Innovative Modality of Cancer Therapy: From CNS to Thoracic Malignancies and Beyond
|
Oct 31, 2023 |
|
Naval Daver, MD - Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
|
Oct 30, 2023 |
|
Michael R. Savona, MD / Andrew M. Brunner, MD - Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
|
Oct 30, 2023 |
|
Stephen V. Liu, MD - A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations
|
Oct 23, 2023 |
|
Guillermo Garcia-Manero, MD / Amy E. DeZern, MD, MHS - The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
|
Oct 06, 2023 |
|
William G. Wierda, MD, PhD, Nicole Lamanna, MD - Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents and Innovative Combinations
|
Oct 06, 2023 |
|
Sagar Lonial, MD, FACP, Krina Patel, MD, MSc - Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T and Antibody Options to Enhance Patient Care
|
Oct 06, 2023 |
|
Melissa L. Johnson, MD - Taking Aim With the Next Wave of Antibody–Drug Conjugates in NSCLC: Rational Strategies for Addressing the Unmet Needs of Diverse Patient Populations With TROP2- and HER3-Targeting Therapies and Other ADC-Based Regimens
|
Oct 06, 2023 |
|
Richard Keen, PhD, FRCP, Edna E. Mancilla, MD - Can YOU Avoid Iatrogenic Harm? Understanding and Identifying Fibrodysplasia Ossificans Progressiva
|
Sep 20, 2023 |
|
Stacy E. Croteau, MD, MMS, Steven W. Pipe, MD - Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategies in Hemophilia A
|
Sep 20, 2023 |
|
David J. Kuter, MD, DPhil / Cindy Neunert, MD, MSCS - New Rules for Overcoming ITP: Guidance on Later-Line Care, the Role of BTKi, and Improving Patient Outcomes
|
Aug 22, 2023 |
|
Jennifer Woyach, MD - Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy
|
Aug 21, 2023 |
|
Mark J. Levis, MD, PhD - Finding the Key to Better Outcomes in FLT3-Mutated AML: Guidance on New Evidence With Next-Gen FLT3 Inhibitors
|
Aug 11, 2023 |
|
Alexander Drilon, MD - Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors
|
Aug 11, 2023 |
|
Ruben A. Mesa, MD, FACP - Taking the Targeted Option for Myelofibrosis: Insights on Modern JAKi Platforms and Emerging Therapeutics
|
Aug 07, 2023 |
|
Robert Z. Orlowski, MD, PhD - The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms
|
Jul 28, 2023 |
|
Guillermo Garcia-Manero, MD - The Team Takes Command in MDS: Guidance on Diagnostic and Treatment Principles for Risk-Based Care and Beyond
|
Jul 28, 2023 |
|
Stephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer Care
|
Jul 28, 2023 |
|
Prof. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies
|
Jul 28, 2023 |
|
Prof. Thomas Cluzeau, MD, PhD - “Intensity” With Efficacy in Acute Myeloid Leukemia (AML): Developing Modern, Intensive Upfront Platforms for Challenging Disease Presentations
|
Jul 28, 2023 |
|
Pasi A. Jänne, MD, PhD - A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLC: The Latest Evidence and Practical Guidance for Biomarker Testing and Individualized Treatment Selection and Sequencing
|
Jul 28, 2023 |
|
Steven W. Pipe, MD - Leading the Change in Hemophilia A: Guidance on Enhancing Prophylactic Care With Innovative EHL FVIII Products
|
Jul 28, 2023 |
|
Ghassan Abou-Alfa, MD, MBA - Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms
|
Jul 06, 2023 |
|
Naval Daver, MD - Pushing Innovation in AML: Real-World Integration of Modern Therapeutics Into Personalized Patient Management
|
Jul 06, 2023 |
|
David M. O'Malley, MD - Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum
|
Jul 05, 2023 |
|
Sumanta Kumar Pal, MD, FASCO - Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum
|
Jul 05, 2023 |
|
Jason J. Luke, MD, FACP - Immunotherapy for the Win Against Melanoma: Strategies for Integrating Innovative and Next-Generation Immunotherapy Options
|
Jun 30, 2023 |
|
Matthew S. Davids, MD, MMSc - Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies
|
Jun 30, 2023 |
|
Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research
|
Jun 30, 2023 |
|
Barbara Burtness, MD - Building on the Immunotherapy Foundation for Head and Neck Cancer: Lessons Learned, Practical Guidance, and Next Steps in Care
|
Jun 29, 2023 |
|
Elena Elimova, MD, M.Sc., FRcPC - Polishing Management Protocols in HER2-Expressing GI Cancers With Targeted Agents: A Focus on Refining Team-Based Strategies to Individualize BTC and GEA Care
|
Jun 28, 2023 |
|
Luke Maese, DO, Rachel Rau, MD - Building a Foundation for Enhanced Outcomes in Pediatric ALL: Guidance on the Asparaginase Component of Modern Therapy
|
Jun 27, 2023 |
|
Kimberly Halla, MSN, FNP-C - Expert Nursing Insights on Personalized Care for Gynecologic Cancers: Educating and Supporting Patients on the Latest Therapeutic Approaches
|
Jun 08, 2023 |
|
Laura Klesse, MD, PhD / Carlos G. Romo, MD - The Bedrock of Personalized NF1 Care: Fundamentals of Managing NF1-Associated PNs and Other Tumors With Innovative Targeted Therapy
|
Jun 06, 2023 |
|
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, Zahra Mahmoudjafari, PharmD, MBA, BCOP - Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy
|
Jun 01, 2023 |
|
Linda R. Duska, MD, MPH / Debra L. Richardson, MD, FACS, FACOG - Upgrading the Treatment Algorithm for Advanced Ovarian Cancer: Expert Tips, Tools, and Patient Care Strategies for Making the Most of PARP Inhibitors Across the Disease Continuum
|
Jun 01, 2023 |
|
Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Leading Change, Leading Advances in CLL Care: Guidance on Delivering Modern Targeted and Cellular Therapeutics
|
Jun 01, 2023 |
|
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering Effective Care With BCMA Antibodies and Cellular Therapy
|
Jun 01, 2023 |
|
Brenda Martone, MSN, ANP-BC, AOCNP - Meeting Patient Needs Through Optimal Nursing Strategies in Personalized Bladder Cancer Care
|
Jun 01, 2023 |
|
Marianne Davies, DNP, ACNP, AOCNP, FAAN - Nurses at the Forefront of the Continuing Success Story of Immunotherapy in NSCLC: Best Practices for Guiding and Supporting Patients Through Treatment and Survivorship
|
Jun 01, 2023 |
|
Jonathan D. Spicer, MD, PhD, FRCSC - Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC
|
Jun 01, 2023 |
|
Catherine Shu, MD / Brendon M. Stiles, MD - Bringing Precision Lung Cancer Care to the Perioperative Space: How to Maximize the Impact of EGFR-Targeted Therapy in Resectable NSCLC
|
Jun 01, 2023 |
|
Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Real-World Nursing Solutions for AML Care: Insights on the Effective and Safe Delivery of Innovative Therapeutics
|
Apr 28, 2023 |
|
Stuart J. Schnitt, MD - A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment
|
Apr 28, 2023 |
|
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Refining Precision Decisions in NSCLC With Common and Less Common EGFR Mutations: Navigating Testing and Treatment Throughout the Disease Continuum
|
Apr 26, 2023 |
|
Jennifer Wargo, MD, MMSc - Harnessing the Power of Immunotherapy in Resectable Melanoma: Guidance for Delivering Effective Adjuvant and Neoadjuvant Strategies
|
Apr 26, 2023 |
|
Laura S. Dominici, MD, FACS - Navigating Complex Decisions at the Intersection of Local and Systemic Management of Early Breast Cancer
|
Apr 26, 2023 |
|
David M. O'Malley, MD - Immunotherapy as a Treatment Cornerstone for Advanced Endometrial Cancer: Personalizing Patient Care
|
Apr 26, 2023 |
|
Emily K. Dotson, PharmD, BCOP - Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy
|
Apr 26, 2023 |
|
Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice
|
Apr 18, 2023 |
|
Riad Salem, MD, MBA, Mark Yarchoan, MD - Essential Conversations for HCC: Radiology-Oncology Collaboration and Immunotherapy Advances in Intermediate and Advanced Disease
|
Apr 13, 2023 |
|
Naval Daver, MD, Joseph D. Khoury, MD, FCAP - The Precision Team in AML: Exploring Pathologist-Informed Clinical Decisions in Challenging AML Settings
|
Apr 13, 2023 |
|
Rami Komrokji, MD - Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment
|
Apr 13, 2023 |
|
Stephanie Lee, MD, MPH - Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease
|
Apr 06, 2023 |
|
Tricia Cottrell, MD, PhD, Lynette M. Sholl, MD - Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment
|
Apr 06, 2023 |
|
Aaron T. Gerds, MD, MS / John Mascarenhas, MD - Shaping Modern Management of Myelofibrosis: Guidance on the Conjunction of Targeted Therapy and AlloHCT
|
Mar 29, 2023 |
|
Janis Taube, MD, MSc - Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment
|
Mar 28, 2023 |
|
Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum
|
Mar 28, 2023 |
|
Thomas G. Martin, III, MD, Krina Patel, MD, MSc - Hitting the BCMA Target in Multiple Myeloma: Insights on CAR-T Therapy and Innovative Antibody Options
|
Mar 28, 2023 |
|
Mazyar Shadman, MD, MPH, Peter A. Riedell, MD - Finding Treatment Synergy in CLL: Expert Consults on Advances With Targeted and Cellular Therapy
|
Mar 28, 2023 |
|
Robert Z. Orlowski, MD, PhD - "House Rules" for Innovative Therapy in Multiple Myeloma: Guidance on Integrating Monoclonal Antibodies and BCMA and Non-BCMA Options Into Patient Care
|
Mar 28, 2023 |
|
James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes
|
Mar 28, 2023 |
|
Jacob Sands, MD - Facilitating Progress in the Treatment of SCLC: How to Optimize the Use of Current Systemic Options and Accelerate the Clinical Transition of Investigational Approaches
|
Mar 28, 2023 |
|
Stephen V. Liu, MD - Perfecting Precision in Modern NSCLC Practice: Are You Optimally Integrating Biomarker-Driven Therapy?
|
Mar 28, 2023 |
|
Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Answers to Key Questions About Antibody–Drug Conjugates in NSCLC
|
Mar 28, 2023 |
|
Olalekan Oluwole, MBBS, MD - The Time Is Now for Outpatient CAR-T: Essential Infrastructure, Lessons From Transplant, and New Evidence
|
Mar 28, 2023 |
|
Nicole Lamanna, MD - Building a Safety-Centric Culture in B-Cell Cancers: Interprofessional Insights on Optimizing BTKi Efficacy Through Safety Management
|
Mar 28, 2023 |
|
Sumanta Kumar Pal, MD, FASCO - Breaking New Ground in RCC Management: Expert Guidance on Leveraging Therapeutic Strategies
|
Mar 14, 2023 |
|
Matthew R. Smith, MD, PhD - Expanding Use of Hormonal Therapeutic Strategies in Prostate Cancer: Clinical Evidence and Practical Considerations for Individualized, Patient-Centered Care
|
Mar 14, 2023 |
|
Prof. Mohamad Mohty, Christine N. Duncan, MD - New Rules for VOD/SOS: Modern Risk Assessment, Diagnostic Principles, and Innovative Treatment
|
Mar 14, 2023 |
|
Jennifer Woyach, MD - Real-World Challenges and Solutions with BTKi in CLL: Therapeutic Insights for Community Practice
|
Mar 14, 2023 |
|
Ravin Ratan, MD, M.Ed - Addressing Key Questions About the Latest Diagnostic and Therapeutic Advances in Desmoid Tumors
|
Mar 10, 2023 |
|
John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL
|
Mar 01, 2023 |
|
Loretta J. Nastoupil, MD - Innovation Now for Follicular Lymphoma: New Evidence for Immunotherapy, Targeted, and Chemo-Free Options
|
Mar 01, 2023 |
|
Shannon N. Westin, MD, MPH - New Horizons for Advanced Endometrial Cancer Treatment: Utilizing Innovative Immunotherapies and Other Novel Approaches
|
Mar 01, 2023 |
|
Jessica Donington, MD, Catherine Shu, MD - EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know
|
Mar 01, 2023 |
|
Rachna T. Shroff, MD, FASCO - Getting Personal With Advanced BTC: Insights on Personalizing Upfront and Sequential Care With Immunotherapy and Targeted Agents
|
Mar 01, 2023 |
|
Nasser Altorki, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances
|
Mar 01, 2023 |
|
Vivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other Cancers
|
Mar 01, 2023 |
|
Ghassan Abou-Alfa, MD, MBA - The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond
|
Mar 01, 2023 |
|
Nikhil C. Munshi, MD - The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes
|
Feb 02, 2023 |
|
Nathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC
|
Feb 02, 2023 |
|
Erika Hamilton, MD - Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer
|
Jan 27, 2023 |
|
Prof. John G. Gribben, MD, DSc - Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment
|
Jan 27, 2023 |
|
Grzegorz (Greg) Nowakowski, MD - Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care
|
Jan 27, 2023 |
|
Prof. Hans Gelderblom, MD - New Evidence Now for Targeted Therapy in TGCT
|
Jan 27, 2023 |
|
Guillermo Garcia-Manero, MD - The Future is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient Management
|
Jan 11, 2023 |
|
Professor Peter Schmid, FRCP, MD, PhD - TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments
|
Jan 06, 2023 |
|
Steven Brem, MD - Setting Our Sights on Improved Outcomes in Glioblastoma: State-of-the-Art Care With Tumor Treating Fields and Other Innovative Approaches
|
Jan 06, 2023 |
|
Rana R. McKay, MD, Alicia K. Morgans, MD, MPH - Alicia K. Morgans, MD, MPH - Case by Case: Maximizing Personalized Approaches to Prostate Cancer
|
Jan 06, 2023 |
|
Petros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All
|
Jan 06, 2023 |
|
Javid Moslehi, MD - Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis, and Management of Myocarditis and Other Cardiac Immune-Related Adverse Events
|
Jan 04, 2023 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 1: Why Are We Talking About VTE?
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 2: Tools for Unmasking VTE Quickly
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 3: Anticoagulation: When to Use It, With What, and for How Long?
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 4: How Can We Talk About VTE to Our Patients?
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 5: Knocking Down Barriers in Transitions of Care
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 6: What Is Real-World Evidence and How Is It Relevant and Important in VTE?
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 7: How Should VTE Be Managed in Patients With Obesity?
|
Dec 19, 2022 |
|
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 8: VTE in Cancer: How Concerning Is It and What Do We Do About It?
|
Dec 19, 2022 |
|
Catherine M. Broome, MD - Following the Diagnostic Pathway for Cold Agglutinin Disease
|
Dec 19, 2022 |
|
Sumanta Kumar Pal, MD, FASCO - RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World
|
Dec 19, 2022 |
|
Amit Singal, MD, MS - It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration and Modern Therapeutics
|
Dec 19, 2022 |
|
Caron Jacobson, MD - Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care
|
Nov 30, 2022 |
|
Daniel J. George, MD - Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?
|
Nov 30, 2022 |
|
Erik P. Sulman, MD, PhD - Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors
|
Nov 22, 2022 |
|
Nasser Altorki, MD - Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right
|
Nov 17, 2022 |
|
Alicia K. Morgans, MD, MPH - Creating a Roadmap for Modern Prostate Cancer Treatment: How to Use the Most Recent Evidence on Novel Therapeutic Strategies and Shared Decision-Making to Personalize Patient Care
|
Nov 17, 2022 |
|
Morie A. Gertz, MD - Don’t Miss the Rare When Diagnosing and Treating Autoimmune Hemolytic Anemia: Focus on CAD
|
Nov 14, 2022 |
|
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations
|
Nov 08, 2022 |
|
Sagar Lonial, MD, FACP - An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA Antibodies
|
Oct 28, 2022 |
|
Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions
|
Oct 28, 2022 |
|
Naval Daver, MD, Amir T. Fathi, MD - The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes
|
Oct 28, 2022 |
|
Brendon M. Stiles, MD - Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings
|
Oct 28, 2022 |
|
Marina Chiara Garassino, MD - Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung Cancer
|
Oct 28, 2022 |
|
Sagar Lonial, MD, FACP - Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies
|
Oct 28, 2022 |
|
Scott T. Tagawa, MD, MS, FACP - Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates
|
Oct 28, 2022 |
|
Praneetha Thulasi, MD, Jonathan L. Kaufman, MD - The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity
|
Oct 28, 2022 |
|
Nicole Lamanna, MD / Deborah M. Stephens, DO - Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices
|
Oct 28, 2022 |
|
Professor Aleix Prat, MD, PhD - Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients
|
Oct 20, 2022 |
|
Guillermo Garcia-Manero, MD; Gail J. Roboz, MD - The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes
|
Oct 20, 2022 |
|
Sara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer
|
Oct 20, 2022 |
|
Javier Cortes, MD, PhD - SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes With Novel ER-Targeting Therapies
|
Oct 19, 2022 |
|
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease
|
Oct 04, 2022 |
|
Marcia S. Brose, MD, PhD, FASCO - Optimizing NTRK Fusion Testing and TRK Inhibition in Thyroid Cancer: Team-Based Approaches for Enhanced Outcomes
|
Oct 04, 2022 |
|
Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies
|
Sep 22, 2022 |
|
Alexander Drilon, MD - Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC
|
Sep 19, 2022 |
|
Ritu Salani, MD, MBA - Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence
|
Sep 06, 2022 |
|
Aditya Bardia, MD, MPH - Candid Conversations and Clinical Consults in Community Context: Practical Guidance for Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer Clinical Care
|
Aug 29, 2022 |
|
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action
|
Aug 25, 2022 |
|
Alexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment
|
Aug 25, 2022 |
|
Elena Elez, MD, PhD - Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents
|
Aug 11, 2022 |
|
Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options
|
Aug 11, 2022 |
|
Prof. Carmelo Rizzari - The Path for Better Outcomes in ALL: Integrating Modern Asparaginase Compounds Into the Care of Pediatric, AYA, and Adult Patients
|
Aug 10, 2022 |
|
Sagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
|
Aug 09, 2022 |
|
Yelena Y. Janjigian, MD - Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?
|
Aug 09, 2022 |
|
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL
|
Aug 09, 2022 |
|
Michael B. Atkins, MD - Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease
|
Aug 05, 2022 |
|
Jason Westin, MD, MS, FACP - Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
|
Aug 05, 2022 |
|
Hussein A. Tawbi, MD, PhD - New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease
|
Aug 05, 2022 |
|
Jacob Sands, MD - Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes
|
Aug 05, 2022 |
|
Anthony R. Mato, MD, MSCE - Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care
|
Aug 02, 2022 |
|
Prof. Dr. med. Stephan Stilgenbauer - New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management
|
Jul 25, 2022 |
|
Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice
|
Jul 22, 2022 |
|
Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum
|
Jul 22, 2022 |
|
Karl D. Lewis, MD - Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment
|
Jul 21, 2022 |
|
Riad Salem, MD, MBA - Making Headway Towards Better Outcomes in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Multidisciplinary Tumor Board on Implementing Novel Locoregional and Systemic Approaches
|
Jul 21, 2022 |
|
Robert I. Haddad, MD - The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care
|
Jul 20, 2022 |
|
David P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease
|
Jul 20, 2022 |
|
Aditya Bardia, MD, MPH - Navigating the Shifting Treatment Paradigm in ER+/HER2- Breast Cancer: Harnessing Modern Treatment Options and the Expanding Evidence Base to Better Patient Care and Outcomes in Early and Advanced Disease
|
Jul 20, 2022 |
|
Gail J. Roboz, MD - The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care
|
Jul 20, 2022 |
|
Nina Shah, MD - The "Myelennial" Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes
|
Jul 20, 2022 |
|
Toni K. Choueiri, MD - Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care
|
Jul 19, 2022 |
|
Richard S. Finn, MD - Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care
|
Jul 12, 2022 |
|
Zev A. Wainberg, MD - Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients: A Strategy to Amplify Immune Response and Enhance or Restore Antitumor Activity
|
Jul 08, 2022 |
|
Stuart S. Winter, MD - Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds
|
Jul 08, 2022 |
|
Jeanne M. Palmer, MD - The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting
|
Jul 08, 2022 |
|
Nelson Chao, MD, MBA - Upgrading the VOD/SOS Management Tool Kit: Guidance for Effective Diagnostic Confirmation, Grading, and Treatment
|
Jul 08, 2022 |
|
Amber C. King, PharmD, BCOP - Making Sense of New Standards for CLL: Pharmacist Insights on Targeted Therapy and the Delivery of Team-Based Care
|
Jul 06, 2022 |
|
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT
|
Jul 06, 2022 |
|
John N. Allan, MD - Reaping the Rewards of Innovative Care in CLL: From Targeted Strategies to Cellular Therapy
|
Jul 06, 2022 |
|
Kurt A. Schalper, MD, PhD - Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors
|
Jul 04, 2022 |
|
Leslie Kean, MD, PhD - Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols
|
Jul 04, 2022 |
|
Michael R. Bishop, MD - CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma
|
Jul 04, 2022 |
|
Matthew R. Smith, MD, PhD - Realizing the Potential of Novel Treatment Intensification Strategies for Metastatic Castration-Sensitive Prostate Cancer: The Experts’ Take on Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care
|
Jun 29, 2022 |
|
Stephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care
|
Jun 29, 2022 |
|
Petros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease Continuum
|
Jun 24, 2022 |
|
Nancy P. Moldawer, RN, MSN - Aligning Nursing Care Strategies With Evolving Patient Needs in RCC: Interprofessional Insights on Optimizing Outcomes With Novel Targeted and Immune-Based Therapies
|
Jun 16, 2022 |
|
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs
|
Jun 16, 2022 |
|
Amy Goodrich, CRNP - Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients
|
Jun 14, 2022 |
|
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community
|
Jun 14, 2022 |
|
Nasser Altorki, MD - How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC
|
Jun 14, 2022 |
|
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies
|
May 30, 2022 |
|
Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers
|
May 30, 2022 |
|
Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do
|
May 25, 2022 |
|
Erika Hamilton, MD - How to Harness Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer: New Goals and Better Tools to Close the Gaps
|
May 23, 2022 |
|
Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC
|
May 23, 2022 |
|
Nina Shah, MD - Mapping the Therapeutic Odyssey in Multiple Myeloma: Interprofessional Guidance on Evidence-Based Treatment Selection and Sequencing
|
May 19, 2022 |
|
Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice
|
May 19, 2022 |
|
Henry M. Kuerer, MD, PhD, FACS - Expanding the Benefits of PARP Inhibitor Therapy to More Patients With Breast Cancer and Earlier Disease Settings: Multidisciplinary Perspectives on How to Maximize the Potential of PARP Inhibitors and Optimize Their Use as Part of Multimodal Management of Breast Cancer
|
May 19, 2022 |
|
Elizabeth Eaman, MD - Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations
|
May 16, 2022 |
|
Bhavana Pothuri, MD, MS - Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer
|
May 16, 2022 |
|
John J. Russell, MD - Cancer Control Through Early Blood-Based Detection: Perspectives on Integrating Innovative Multicancer Early Detection Tests in the Primary Care Setting
|
May 05, 2022 |
|
Bradley J. Monk, MD, FACS, FACOG - When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum
|
May 04, 2022 |
|
Tanios Bekaii-Saab, MD - Dialing in the Dose: Reviewing Recent Evidence and Team-Based Strategies to Personalize and Optimize Patient Care in Metastatic Colorectal Cancer
|
May 04, 2022 |
|
Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies
|
Apr 29, 2022 |
|
Anthony R. Mato, MD, MSCE - Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency
|
Apr 29, 2022 |
|
Sumanta Kumar Pal, MD, FASCO - Navigating Evolving Standards of Care in Renal Cell Carcinoma: Expert Insights on Selecting and Sequencing Targeted and Immunotherapy Options and a Look at Emerging Strategies
|
Apr 22, 2022 |
|
Geoffrey Barnes, MD, MSc - Primary Care Call to Action for VTE Management: Sharpening Skills in Recognition, Treatment, and Secondary Prevention
|
Apr 22, 2022 |
|
Henry M. Kuerer, MD, PhD, FACS / Heather L. McArthur, MD, MPH - Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches
|
Apr 13, 2022 |
|
Milind Javle, MD - Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine
|
Apr 11, 2022 |
|
Cindy Neunert, MD, MSCS - Modern Management of ITP: Thinking Beyond the Conventional Therapies
|
Apr 08, 2022 |
|
Petros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions
|
Apr 06, 2022 |
|
Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC - Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?
|
Apr 04, 2022 |
|
Jennifer Wargo, MD, MMSc - Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options
|
Apr 01, 2022 |
|
Stephen V. Liu, MD - Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors
|
Mar 31, 2022 |
|
Robert Dreicer, MD, MS, MACP, FASCO - Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults
|
Mar 30, 2022 |
|
Richard S. Finn, MD - Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape
|
Mar 29, 2022 |
|
Mark S. Freedman, MD - Leveraging S1PR Modulators to Provide Patient-Centered MS Care: An Expert-Driven Review of the Data
|
Mar 29, 2022 |
|
Boris Sepesi, MD / Tina Cascone, MD, PhD - Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do
|
Mar 16, 2022 |
|
Anthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers
|
Mar 16, 2022 |
|
William D. Tap, MD - Practice Points in TGCT: Updates on Safe Use of Novel Systemic Options
|
Feb 23, 2022 |
|
Michael Heinrich, MD - Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team
|
Feb 23, 2022 |
|
Suzanne Lentzsch, MD, PhD - A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey
|
Feb 22, 2022 |
|
Professor Thomas Powles, MBBS, MRCP, MD - Carrying Through in Advanced/Metastatic Urothelial Carcinoma: Expert Perspectives on Recent Practice‐Changing Data and the Practicalities of Individualizing and Continuing Care With Novel Immunotherapy Maintenance Strategies
|
Feb 22, 2022 |
|
Carlos M. de Castro, MD - Upstream and Downstream Targeting of the Complement Pathway to Manage PNH: Current and Emerging Inhibitors
|
Feb 17, 2022 |
|
Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care
|
Feb 15, 2022 |
|
Sara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor Therapy
|
Feb 03, 2022 |
|
Biree Andemariam, MD - The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities
|
Feb 01, 2022 |
|
Erika Hamilton, MD - Expanding Treatment Options in ER+/HER2- Breast Cancer: Expert Perspectives on the Rapidly Emerging Role of SERDs, SERMs, and SERCAs, and the Practical Considerations of Leveraging Established and Innovative Therapies
|
Jan 28, 2022 |
|
Steven Brem, MD - A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches
|
Jan 26, 2022 |
|
Nathan H. Fowler, MD - A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care
|
Jan 26, 2022 |
|
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease
|
Jan 24, 2022 |
|
John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management
|
Jan 20, 2022 |
|
Christopher Baugh, MD, MBA & Mark M. Awad, MD, PhD - Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice
|
Jan 20, 2022 |
|
John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci - Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management
|
Jan 12, 2022 |
|
Robert Dreicer, MD, MS, MACP, FASCO/Pedro C. Barata, MD, MSc - Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer
|
Jan 11, 2022 |
|
Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers
|
Jan 11, 2022 |
|
Petros Grivas, MD, PhD - Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies
|
Jan 10, 2022 |
|
Sumanta Kumar Pal, MD, FASCO - Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?
|
Jan 06, 2022 |
|
David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC
|
Dec 20, 2021 |
|
Amit Singal, MD, MS - Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies
|
Dec 20, 2021 |
|
Joyce O’Shaughnessy, MD - Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors
|
Dec 16, 2021 |
|
Javid Moslehi, MD - Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?
|
Dec 16, 2021 |
|
Nirav Shah, MD, MS - Visualizing Progress With BTK Inhibitors: An Animated Journey Through the Mechanisms of Covalent and Noncovalent Options
|
Dec 09, 2021 |
|
Jubilee Brown, MD - Changing Tides in Advanced Endometrial Cancer: A Visual Exploration of Current and Emerging Strategies to Maximize the Potential of Cancer Immunotherapies
|
Dec 09, 2021 |
|
Lynette M. Sholl, MD - Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings
|
Dec 08, 2021 |
|
Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers
|
Dec 08, 2021 |
|
Jonathan W. Goldman, MD - Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?
|
Nov 29, 2021 |
|
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care
|
Nov 16, 2021 |
|
Andrew J. Wagner, MD, PhD - Overcoming the Challenges of Diverse TGCT Presentations: Diagnostic and Treatment Principles for the Multidisciplinary Team
|
Nov 09, 2021 |
|
Kurt A. Schalper, MD, PhD - Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy
|
Nov 05, 2021 |
|
Peter A. Kouides, MD - Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care With Current and Emerging Management Strategies
|
Oct 25, 2021 |
|
Nicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential Care
|
Oct 19, 2021 |
|
Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
|
Oct 19, 2021 |
|
Srdan Verstovsek, MD, PhD / Ruben A. Mesa, MD, FACP - Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics
|
Oct 19, 2021 |
|
Anthony R. Mato, MD, MSCE - Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies
|
Oct 14, 2021 |
|
Sagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care
|
Oct 13, 2021 |
|
Milind Javle, MD - Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly Available and Innovative Therapeutics to Deliver Precision-Based Care
|
Oct 12, 2021 |
|
Jared Weiss, MD - Raising the Bar for Patient Outcomes With Transcription Inhibition and Other New Options in the Treatment Arsenal for SCLC: Rationale, Mechanisms of Action, Latest Data, and Practicalities of Clinical Use in Oncology Practice
|
Oct 12, 2021 |
|
Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL
|
Oct 11, 2021 |
|
Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment
|
Oct 11, 2021 |
|
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA/ Kathryn Maples, PharmD, BCOP / Tim J. Peterson, PharmD, BCOP -Making Sense of the New World of Myeloma Care: Pharmacy Perspectives on Novel Antibodies and BCMA CAR-T Therapy
|
Oct 08, 2021 |
|
Sanam Loghavi, MD - Secondary AML Through the Microscope: A Pathology-Informed Guide to Modern Diagnostic and Treatment Principles
|
Oct 06, 2021 |
|
Stephen V. Liu, MD - Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical
|
Oct 06, 2021 |
|
Stephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment
|
Sep 29, 2021 |
|
Jamie E. Chaft, MD - Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC
|
Sep 29, 2021 |
|
Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics
|
Sep 28, 2021 |
|
Nina Shah, MD - Innovation at Warp Speed for Multiple Myeloma: Tumor Board Insights on State-of-the-Art Care
|
Sep 28, 2021 |
|
Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy
|
Sep 15, 2021 |
|
Ian W. Flinn, MD, PhD - Visualizing the Present and Future of CLL: How Innovative Therapies and State-of-the-Art Combinations Are Transforming Patient Care
|
Sep 13, 2021 |
|
Ruben A. Mesa, MD, FACP - A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes
|
Sep 10, 2021 |
|
Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies
|
Aug 31, 2021 |
|
Alok A. Khorana, MD, FACP, FASCO / Robert D. McBane, II, MD - Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care and Shared Decision-Making Strategies to Improve Patient Outcomes
|
Aug 17, 2021 |